Related Experiment Video

Updated: Aug 30, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Treatment failures and relapses in onychomycosis: a stubborn clinical problem

Jorge E Arrese1, Gérald E Piérard

  • 1Department of Dermatopathology, University Medical Center, Liège, Belgium.

Dermatology (Basel, Switzerland)
|October 23, 2003
PubMed

Insights

Onychomycosis treatment outcomes remain uncertain, with current antifungals often failing to guarantee a cure and relapses being common. Therapeutic failures stem from diagnostic issues, improper drug selection, and fungal resistance.

Area of Science:

  • Mycology
  • Dermatology
  • Pharmacology

Background:

  • Onychomycosis, a fungal nail infection, presents therapeutic challenges with uncertain outcomes.
  • Existing short-term antifungal efficacy studies offer contradictory findings on treatment success.
  • Long-term follow-up data on onychomycosis treatment is scarce and unbiased studies are limited.

Purpose of the Study:

  • To critically evaluate the long-term therapeutic outcomes of onychomycoses.
  • To identify the multifactorial causes contributing to treatment failures in fungal nail infections.
  • To assess the clinical relevance of in vitro fungicidal drug data for onychomycosis.

Main Methods:

  • Review of existing literature on onychomycosis treatment outcomes.
  • Analysis of factors influencing therapeutic success and failure.
  • Comparison of in vitro antifungal data with clinical practice observations.

Main Results:

  • Current antifungal treatments do not guarantee complete cure for onychomycoses, with frequent relapses observed.
  • Key factors for therapeutic failure include inaccurate diagnosis, suboptimal antifungal choice or delivery, and fungal resistance mechanisms.
  • The clinical utility of fungicidal activity demonstrated in in vitro studies is questionable for treating onychomycosis.

Conclusions:

  • Long-term therapeutic outcomes for onychomycoses are unpredictable, necessitating improved diagnostic and treatment strategies.
  • Addressing diagnostic accuracy and optimizing antifungal selection and delivery are crucial for improving patient outcomes.
  • Further research is needed to bridge the gap between in vitro antifungal efficacy and clinical effectiveness in onychomycosis management.

More Related Videos

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis08:48

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis

Published on: March 19, 2019

Related Concept Videos

Acne Infection01:27

Acne Infection

Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Trichomoniasis01:18

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...